Peroxisome Proliferator-Activated Receptor Agonists: Do They Increase Cardiovascular Risk?

• Main Authors: Ahmad Aljada, Kshitij Ashwin Shah, Shaker A. Mousa
• Format: Article
• Language: English
• Published: Hindawi Limited 2009-01-01
• Series: PPAR Research
• Online Access: http://dx.doi.org/10.1155/2009/460764

Cardiovascular disease is a major cause of morbidity and mortality among people with type 2 diabetes mellitus. The peroxisome proliferator-activated receptor (PPAR) agonists have a significant role on glucose and fat metabolism. Thiazolidinediones (TZDs) are predominantly PPARγ agonists, and their primary benefit appears to be the prevention of diabetic complications by improving glycemic control and lipid profile. Recently, the cardiovascular safety of rosiglitazone was brought to center stage following meta analyses and the interim analysis of the RECORD trial. Current evidence points to rosiglitazone having a greater risk of myocardial ischemic events than placebo, metformin, or sulfonylureas. This review article discusses the mechanism of action of PPAR agonists and correlates it with clinical and laboratory outcomes in the published literature. In addition, this review article attempts to discuss some of the molecular mechanisms regarding the association between TZDs therapy and the nontraditional cardiovascular risks.